艾普奈珠单抗用于既往两种至四种预防治疗失败的偏头痛患者预防治疗的安全性和有效性(DELIVER):一项多臂、随机、双盲、安慰剂对照、3b期试验
DELIVER是一项多中心、多臂、3b期试验,纳入891例有2至4种既往预防治疗失败的成人偏头痛患者,随机接受艾普奈珠单抗100 mg、300 mg或安慰剂。第1至12周每月偏头痛天数较基线变化:100 mg组-4.8天、300 mg组-5.3天、安慰剂组-2.1天,与安慰剂差异均显著。治疗中出现的不良事件三组分别为42%、41%、40%,安全性可接受。
要点
- 艾普奈珠单抗100 mg和300 mg较安慰剂显著减少每月偏头痛天数。
- 治疗中出现的不良事件发生率三组相似,最常见为COVID-19。
- 严重不良事件不常见,包括过敏反应和COVID-19。
核心结论
- 在有2至4种既往预防治疗失败的成人偏头痛患者中,艾普奈珠单抗较安慰剂提供显著的偏头痛预防效果,安全性和耐受性可接受,提示艾普奈珠单抗可能是该患者群体的有效治疗选择。
- 剂量盲法扩展期将为有既往预防治疗失败的偏头痛患者提供额外长期安全性数据。
研究设计与样本
- DELIVER是一项多中心、多臂、3b期试验,包含24周双盲、安慰剂对照期和48周剂量盲法扩展期。
- 从欧洲93个和美国3个共96个研究地点招募成人发作性或慢性偏头痛患者,要求每月偏头痛天数至少4天且有2至4种既往预防治疗失败的记录证据。
- 891例患者按1:1:1随机分配至艾普奈珠单抗100 mg、300 mg或安慰剂,按基线每月头痛天数和 country 分层。
- 主要疗效终点为第1至12周每月偏头痛天数较基线的变化,在完整分析集中评估。
主要发现
- 第1至12周每月偏头痛天数较基线变化:艾普奈珠单抗100 mg组-4.8天(SE 0.37),300 mg组-5.3天(SE 0.37),安慰剂组-2.1天(SE 0.38)。
- 与安慰剂相比,每月偏头痛天数较基线变化的差异:100 mg组-2.7天(95% CI -3.4至-2.0;p<0.0001),300 mg组-3.2天(95% CI -3.9至-2.5;p<0.0001)。
- 治疗中出现的不良事件:100 mg组127/299例(42%),300 mg组120/294例(41%),安慰剂组119/298例(40%)。
- 最常见治疗中出现的不良事件为COVID-19:100 mg组20/299例(7%),300 mg组17/294例(6%),安慰剂组16/298例(5%)。
- 严重不良事件不常见:100 mg组5/299例(2%),300 mg组7/294例(2%),安慰剂组4/298例(1%),包括过敏反应(300 mg组2例)和COVID-19(100 mg组1例、300 mg组1例)。
关键数值与推荐
- 艾普奈珠单抗100 mg组第1至12周每月偏头痛天数较基线变化-4.8天(SE 0.37),与安慰剂差异-2.7天(95% CI -3.4至-2.0;p<0.0001)。
- 艾普奈珠单抗300 mg组第1至12周每月偏头痛天数较基线变化-5.3天(SE 0.37),与安慰剂差异-3.2天(95% CI -3.9至-2.5;p<0.0001)。
- 安慰剂组第1至12周每月偏头痛天数较基线变化-2.1天(SE 0.38)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The monoclonal antibody eptinezumab, which targets calcitonin gene-related peptide, has shown migraine preventive effects starting the day following infusion and acceptable safety and tolerability in phase 3 trials, but benefits in the subpopulations of patients with previous preventive treatment failures were not examined. We aimed to investigate the safety and efficacy of eptinezumab for migraine prevention in adults with migraine and two-to-four previous preventive treatment failures. METHODS: DELIVER was a multicentre, multi-arm, phase 3b trial comprising a 24-week double-blind, placebo-controlled period and a 48-week dose-blinded extension. We recruited adults with episodic or chronic migraine with at least 4 monthly migraine days (as per International Headache Society guidelines) and documented evidence of two-to-four previous preventive treatment failures within the past 10 years, from 96 study locations across Europe (n=93) and the USA (n=3). Patients were randomly assigned (1:1:1) via a centralised randomisation system, stratified by baseline monthly headache days and country, to eptinezumab 100 mg, eptinezumab 300 mg, or placebo. The primary efficacy endpoint was the change from baseline in mean monthly migraine days (captured using a daily electronic diary) in weeks 1-12, assessed in the full analysis set. All participants and study personnel were masked to study drug assignments. The dose-blinded extension period is ongoing. The trial is registered with ClinicalTrials.gov, NCT04418765, and EudraCT, 2019-004497-25. FINDINGS: Between June 1, 2020, and Oct 7, 2021, 891 individuals were randomly assigned and received at least one dose of study drug (safety population; eptinezumab 100 mg n=299 [34%], eptinezumab 300 mg n=294 [33%], placebo n=298 [33%]). 865 patients completed the placebo-controlled period. The change from baseline to weeks 1-12 in mean monthly migraine days was -4·8 (SE 0·37) with eptinezumab 100 mg, -5·3 (0·37) with eptinezumab 300 mg, and -2·1 (0·38) with placebo. The difference from placebo in change in mean monthly migraine days from baseline was significant with eptinezumab 100 mg (-2·7 [95% CI -3·4 to -2·0]; p<0·0001) and eptinezumab 300 mg (-3·2 [-3·9 to -2·5]; p<0·0001). Treatment-emergent adverse events occurred in 127 (42%) of 299 patients in the eptinezumab 100 mg group, in 120 (41%) of 294 in the eptinezumab 300 mg group, and in 119 (40%) of 298 in the placebo group. The most common treatment-emergent adverse event was COVID-19 (20 [7%] of 299 patients in the eptinezumab 100 mg group, 17 [6%] of 294 in the eptinezumab 300 mg group, and 16 [5%] of 298 in the placebo group). Serious adverse events were uncommon (five [2%] of 299 in the eptinezumab 100 mg group, seven [2%] of 294 in the eptinezumab 300 mg group, four [1%] of 298 in the placebo group) and included anaphylactic reaction (eptinezumab 300 mg n=2) and COVID-19 (eptinezumab 100 mg n=1 and eptinezumab 300 mg n=1). INTERPRETATION: In adults with migraine and two-to-four previous preventive treatment failures, eptinezumab provided significant migraine preventive effects compared with placebo, with acceptable safety and tolerability, indicating that eptinezumab might be an effective treatment option for this patient population. The dose-blinded extension period will provide additional long-term safety data in patients with migraine and previous preventive treatment failures. FUNDING: H Lundbeck.
引用
- Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022. PMID: 35716692. doi:10.1016/S1474-4422(22)00185-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。